Advertisement.
Advertisement.
Advertisement
Advertisement.
ANRO Alto Neuroscience Inc.
93
| Market Cap | $389.55M |
| Volume | 74,699.00 |
| 52-Wk High | $24.00 |
| 52-Wk Low | $9.40 |
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
Business Wire•1 day ago
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Share to Feed
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the...
Business Wire•11 days ago
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ALTO-101, a novel PDE4 inhibitor in...
Business Wire•1 month ago
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year 2024 Bay Area Award finalist by EY. Now in its 38th...
Business Wire•1 month ago
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit...
Business Wire•2 months ago
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced the expansion of the Companys leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr...
Business Wire•2 months ago
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. Our teams commitment to developing...
Business Wire•2 months ago
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced upcoming data presentations that highlight the companys precision psychiatry pipeline and biomarker-based analyses at the Society of...
Business Wire•3 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly•4 months ago
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress. 2024 is shaping up to be a...
Business Wire•4 months ago